Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Growth in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,550,000 shares, an increase of 14.0% from the January 15th total of 1,360,000 shares. Currently, 11.8% of the shares of the company are short sold. Based on an average trading volume of 336,000 shares, the short-interest ratio is currently 4.6 days.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Maxim Group raised their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Lake Street Capital initiated coverage on Sensus Healthcare in a research note on Friday, January 31st. They set a "buy" rating and a $18.00 target price for the company. Finally, HC Wainwright lifted their price target on Sensus Healthcare from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday, February 10th.

Sensus Healthcare Stock Down 2.2 %

NASDAQ SRTS traded down $0.13 during midday trading on Wednesday, hitting $5.71. The company had a trading volume of 290,009 shares, compared to its average volume of 424,744. The firm has a fifty day simple moving average of $7.02 and a two-hundred day simple moving average of $6.86. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The stock has a market cap of $93.65 million, a price-to-earnings ratio of 14.29 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, equities analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Sensus Healthcare during the fourth quarter worth $27,000. Barclays PLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth about $35,000. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare during the 3rd quarter valued at about $32,000. BNP Paribas Financial Markets bought a new stake in Sensus Healthcare in the fourth quarter valued at about $47,000. Finally, Geode Capital Management LLC raised its position in Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after purchasing an additional 11,525 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.